IGXT实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 03:59):

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market...

Stats
今日成交量	136 907
平均成交量	98 596.00
市值	28.28M
EPS	$0 ( 2024-03-21 )
下一个收益日期	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.70
ATR14	$0.00400 (2.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Atai Life Sciences N.v.	Buy	0	Convertible Notes
2023-11-28	Atai Life Sciences N.v.	Buy	4 053 750	Warrant (Right to Buy)
2024-03-08	Atai Life Sciences N.v.	Buy	1 000 000	Convertible Notes
2023-10-06	Atai Life Sciences N.v.	Buy	8 500 000	Convertible Notes
2024-03-08	Atai Life Sciences N.v.	Buy	4 000 000	Warrant (Right to Buy)

INSIDER POWER
99.01
Last 94 transactions
Buy: 34 712 521 \| Sell: 605 000

IntelGenx Technologies 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

IntelGenx Technologies 财务报表

Annual	2023
营收:	$1.04M
毛利润:	$-1.46M (-140.52 %)
EPS:	$-0.0568

FY	2023
营收:	$1.04M
毛利润:	$-1.46M (-140.52 %)
EPS:	$-0.0568

FY	2022
营收:	$950 000
毛利润:	$-908 000 (-95.58 %)
EPS:	$-0.0726

FY	2021
营收:	$1.54M
毛利润:	$-721 000 (-46.97 %)
EPS:	$-0.0700

Financial Reports:

No articles found.

IntelGenx Technologies

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

实时更新： IntelGenx Technologies [IGXT]

Upcoming Earnings Alert